Chinese Regulators, Police Intensify Investigation Of Vaccine Producer For Possible Malfeasance, Cover-up
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical has revealed that certain personnel at recently acquired vaccine producer Jiangsu Yanshen Biological Technology are under investigation for possible attempts to cover up lapses in good manufacturing practice standards that led to the release of substandard rabies vaccine doses in 2008
You may also be interested in...
Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation
BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology
Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation
BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology
China's Simcere Pharmaceutical Becomes Beacon For Disclosing GMP Problems At New Vaccine Subsidiary
BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility